KOL | Reginald C BruskewitzGeorge M. O'Brien Center for Benign Urologic Research and Department of Urology, University of Wisconsin-Madison , Madison, Wisconsin. | Department of Urology, Tufts ... |
KOL Resume for Reginald C Bruskewitz
| Year | |
|---|---|
| 2019 | George M. O'Brien Center for Benign Urologic Research and Department of Urology, University of Wisconsin-Madison , Madison, Wisconsin. |
| 2016 | Department of Urology, Tufts University School of Medicine, Boston, Massachusetts Section of Urology, The University of Kansas Medical Center, Kansas City, Kansas, and the American Urological Association |
| 2014 | University of Wisconsin, Madison, WI, USA |
| 2011 | Department of Urology, University of Wisconsin, Madison, Wisconsin American Urological Association Education and Research, Inc., Linthicum Maryland |
| 2010 | Madison, WI |
| 2009 | University of Wisconsin Clinical Science Center, Madison, Wisconsin |
| 2008 | Departments of Urology, School of Medicine and Public Health, University of Wisconsin–Madison, |
| 2006 | Division of Urology, Department of Surgery, University of Wisconsin Medical School, Madison, Wisconsin |
| 2005 | University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792, USA |
| 2004 | From the Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland, Department of Urology, University of Michigan School of Medicine, Ann Arbor, Michigan, Center for Health Sciences, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, Department of Urology, Emory University School of Medicine, Atlanta, Georgia, Urology Health Center, New Port Richey, Florida, Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, and Department of Urology Stanford and Palo Alto Veterans Affairs Medical Center, Palo Alto, California |
| 2003 | Clinical Science Center, University of Wisconsin, Madison, Wisconsin, USA |
| 2000 | School of Medicine, University of Wisconsin, Madison, Wisconsin |
| 1999 | Scottsdale, AZ (Larson), Minneapolis, MN (Utz), Madison, WI (Bruskewitz), Rochester, NY (Mayer), Rochester, MN (Blute), Detroit, MI (Diokno), Seattle, WA (Gibbons), Lakeland, FL (Wilson), New York NY (Kaplan) Presented by Dr. Larson. Division of Urology, Department of Surgery, Madison Medical Center, Madison, Wisconsin, USA From the Departments of Urology, Southmead Hospital, Bristol, East Surrey Hospital, Surrey and St. Bartholomew's Hospital, London, United Kingdom, Urology Clinic der RWTH Aachen, Aachen, Germany, Tampere University Hospital, Tampere, Finland, Mayo Clinic, Rochester, Minnesota, University Hospital MAS, Malmoe, Sweden, University Hospital, Maastricht, The Netherlands, Hospital de Curry Cabral, Lisbon, Portugal, Herlev Hospital, Frederiksberg University Hospital, Copenhagen, Denmark, University of Wisconsin, Madison, Wisconsin, and Merck Research Laboratories, Rahway, New Jersey and Brussels, Belgium Accepted for publication November 20, 1998. (Barrett) Financial interest and/or other relationship with Merck. The Finasteride Urodynamics Study Group; Additional members: H. Marshall, N. R. Holm, B. Palma, G. Nunes, J. Tyger, B. Uvelius, H. Schatz, R. Gauffin, D. W. De Knijff and E. Richters. Baltimore, MD (Naslund); Port Riley, FL (Perez-Marrero); Dallas, TX (Roehrborn); Madison, WI (Bruskewitz); Atlanta, GA (Issa) (Presentation by Dr. Roehrborn) For the PLESS Study Group; Madison WI (Bruskewitz); Blue Bay, PA (Girman) (Presented by Dr. Bruskewitz) |
| 1998 | From the Cooperative Studies Program of the Research and Development Service, Department of Veterans Affairs, Hines, Illinois, Department of Veterans Affairs Medical and Regional Office Center, White River Junction, Vermont, Dartmouth Medical School, Hanover, New Hampshire, and Department of Surgery, University of Wisconsin Medical School, Madison, Wisconsin Accepted for publication January 16, 1998. Supported by the Cooperative Studies Program of the Department of Veterans Affairs Research and Development Service. (WASSON) Supported by PORT II Grant HS08397 from the Agency for Health Care Policy and Research. University of Florida at Gainesville and Department of Veterans Affairs Medical Center, Gainesville, Florida U.S.A. Division of Urology, Department of Surgery, G5/344 CSC, 600 Highland Avenue, Madison, WI 53792, USA Tel.: +1-608-263-5059; Fax: +1-608-263-0454 e-mail: US |
| 1997 | Division of Urology, Department of Surgery, University of Wisconsin, Madison, Wisconsin U.S.A. From the Department of Surgery, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, Cooperative Studies Program, Veterans Administration Hospital, Hines, Illinois, and Veterans Administration Medical Center, White River Junction, Vermont Viborg Sygehus, Department of Gynecology and Obstetrics, Viborg, Denmark |
| 1996 | Department of Surgery/Urology, University of Wisconsin School of Medicine, Madison, Wisconsin, U.S.A. |
| 1995 | Division of Urology, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, USA Department of Surgery, University of Wisconsin, Madison |
| 1994 | Division of Urology, University of Wisconsin, Madison, Wisconsin, USA Morten JoSnler, Division of Urology, Department of Surgery, University of Wisconsin Hospital and Clinics, Clinical Science Center G5/344, 600 Highland Avenue, Madison, WI 53792, USA. Department of Urology, Clinical Science Center G5/344, University of Wisconsin — Madison, 600 Highland Avenue, WI53792, Madison, Wisconsin, USA University of Minnesota, Minneapolis, Minnesota Mount Sinai School of Medicine, New York, New York |
| 1993 | From the Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey Columbia University, New York Departments of Urology, University of Madison, Madison, Wisconsin Hvidovre University Hospital, Copenhagen, Denmark University Hospitals, Urology Clinics, Basel, Switzerland |
| 1992 | University of Wisconsin Hospital and Clinics, Madison. American Urological Association |
| 1991 | Division of Urology, University of Wisconsin, Madison, Wisconsin |
| 1990 | Center for Health Sciences, University of Wisconsin, Madison, Wisconsin General Internal Medicine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts From the Department of Community and Family Medicine, Dartmouth Medical School, Hanover, New Hampshire Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada |
Reginald C Bruskewitz: Influence Statistics
| Concept | World rank |
|---|---|
| surgeryαreceptor blockers | #1 |
| techniques uroflowmetry | #1 |
| blizzard bell | #1 |
| anesthesia hospitalization | #1 |
| bph turp 1 | #1 |
| cases initial management | #1 |
| guthrie bell | #1 |
| voiding pressures patients | #1 |
| evaluation prostatism | #1 |
| symptom analysis predictor | #1 |
| prostate disease life | #1 |
| patient luts | #1 |
| respect percent area | #1 |
| hyperplasia mixed | #1 |
| qmax modest correlation | #1 |
| initial 3 measurements | #1 |
| maximum flow 7 | #1 |
| symptom score uroflowmetry | #1 |
| uroflowmetry 7 | #1 |
| significance prostatism | #1 |
| retrograde ejaculation incision | #1 |
| hyperplasia cystoscopy | #1 |
| bladder inflammation leukotrienes | #1 |
| turp male prostatectomy | #1 |
| secondary transurethral | #1 |
| associations obstructive symptoms | #1 |
| clinical manifestations benign | #1 |
| studies incision | #1 |
| bphantiandrogen therapy | #1 |
| patients uninhibited | #1 |
| spontaneous uroflowmetry prostatism | #1 |
| waiting moderate | #1 |
| recurrent prostatic tissue | #1 |
| challenge future urodynamic | #1 |
| luts article | #1 |
| urodynamic tests methodology | #1 |
| turp followup visits | #1 |
| impact prostate disease | #1 |
| publication cystoscopy diagnosis | #1 |
| rods transient problems | #1 |
| 159 154 | #1 |
| qol sham | #1 |
| prostatic complaints | #1 |
| indications therapeutic intervention | #1 |
Open the FULL List in Excel | |
Prominent publications by Reginald C Bruskewitz
PURPOSE: We assess the 1-year efficacy and safety of transurethral needle ablation of the prostate compared to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia (BPH).
MATERIALS AND METHODS: A prospective, randomized clinical trial of 121 men 50 years old or older with symptomatic BPH was performed at 7 medical centers across the United States. Of the men 65 (54%) were treated with transurethral needle ablation of the prostate and 56 ...
| Known for Transurethral Resection | Prostatic Hyperplasia | Needle Ablation | Symptomatic Benign | Prostate Treatment |
SERUM PROSTATE SPECIFIC ANTIGEN IS A STRONG PREDICTOR OF FUTURE PROSTATE GROWTH IN MEN WITH BENIGN PROSTATIC HYPERPLASIA
[ PUBLICATION ]
PURPOSE: We analyze patterns of prostate growth in men diagnosed with benign prostatic hyperplasia (BPH) and treated with placebo during 4 years, and determine which baseline parameters were the strongest predictors of growth.
MATERIALS AND METHODS: A total of 3,040 men were enrolled in the 4-year randomized, placebo controlled Proscar Long-Term Efficacy and Safety study. Of these men a subgroup of 10% underwent pelvic magnetic resonance imaging prostate volume measurement at baseline ...
| Known for Specific Antigen | Serum Prostate | 4 Years | Prostatic Hyperplasia | Bph Psa |
PURPOSE: We report the 5-year efficacy and safety of transurethral needle ablation of the prostate (TUNA) compared to transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
MATERIALS AND METHODS: A total of 121 men 50 years or older with LUTS secondary to BPH a minimum of 3 months in duration were enrolled in this prospective, randomized clinical trial at 7 medical centers across the United ...
| Known for Transurethral Resection | Prostatic Hyperplasia | Tuna Turp | Luts Bph | Prostate Treatment |
BACKGROUND: Finasteride is known to improve urinary symptoms in men with benign prostatic hyperplasia, but the extent to which the benefit is sustained and whether finasteride reduces the incidence of related events, including the need for surgery and the development of acute urinary retention, is not known.
METHODS: In this double-blind, randomized, placebo-controlled trial, we studied 3040 men with moderate-to-severe urinary symptoms and enlarged prostate glands who were treated daily ...
| Known for Acute Urinary Retention | Benign Prostatic Hyperplasia | Finasteride Placebo | Surgical Treatment | Reduction Risk |
OBJECTIVES: To determine the effectiveness, safety, and impact on patient quality of life (QOL) of a novel transurethral microwave thermoablation system for the treatment of benign prostatic hyperplasia (BPH).
METHODS: A total of 169 patients with BPH were randomized to undergo a 1-hour microwave (n = 125) or sham (n = 44) procedure using the Urologix Targis thermoablation system on an outpatient basis, without general or regional anesthesia. Symptoms, flow rates, and QOL scores were ...
| Known for Prostatic Hyperplasia | 6 Months | Microwave Treatment | Qol Score | Clinical Trial |
BACKGROUND: Benign prostatic hyperplasia is a progressive, androgen-dependent disease resulting in enlargement of the prostate gland and urinary obstruction. Preventing the conversion of testosterone to its tissue-active form, dihydrotestosterone, by inhibiting the enzyme 5 alpha-reductase could decrease the action of androgens in their target tissues; in the prostate the result might be a decrease in prostatic hyperplasia and therefore in symptoms of urinary obstruction.
METHODS: In a ...
| Known for Prostatic Hyperplasia | Urinary Flow | 5 Day | Decrease Symptoms | Finasteride 1 |
OBJECTIVES: To prospectively evaluate the level of urinary incontinence and its impact on quality of life in patients undergoing radical retropubic prostatectomy.
METHODS: Patients completed a 24-hour pad test together with an incontinence and quality-of-life questionnaire before and after surgery.
RESULTS: Patients were followed up for an average of 7.6 months (range 4.7 to 12.5) after radical prostatectomy. The 24-hour pad test demonstrated that 87% of patients had some incontinence at ...
| Known for Radical Retropubic Prostatectomy | Urinary Incontinence | Quality Life | Surgery Patients | Urine Loss |
A Comparison of Transurethral Surgery with Watchful Waiting for Moderate Symptoms of Benign Prostatic Hyperplasia
[ PUBLICATION ]
BACKGROUND: Transurethral resection of the prostate is the most common surgical treatment for benign prostatic hyperplasia. We conducted a multicenter randomized trial to compare this surgery with watchful waiting in men with moderate symptoms of benign prostatic hyperplasia.
METHODS: Of 800 men over the age of 54 years who were screened between July 1986 and July 1989, 556 (mean [+/- SD] age, 66 +/- 5 years) were studied (280 in the surgery group and 276 in the watchful-waiting group). ...
| Known for Watchful Waiting | Benign Prostatic Hyperplasia | Transurethral Surgery | Moderate Symptoms | Treatment Failure |
OBJECTIVES: • To investigate the Prostatic Urethral Lift (PUL) procedure, a novel, minimally invasive treatment for symptomatic benign prostatic hyperplasia (BPH), which aims to mechanically open the prostatic urethra without ablation or resection. • To demonstrate the safety and feasibility of this procedure and to make an initial assessment of effectiveness.
PATIENTS AND METHODS: • The PULprocedure was performed on 19 men in Australia. • Small suture-based implants were implanted ...
| Known for Prostatic Hyperplasia | Pul Procedure | Urethral Lift | Invasive Treatment | 2 Weeks |
Urinary Retention in Patients with BPH Treated with Finasteride or Placebo over 4 Years
[ PUBLICATION ]
OBJECTIVES: Knowledge regarding the incidence and prevalence of acute urinary retention and the ultimate outcome is very limited. The purpose of the present analysis was to document the natural history and outcomes of acute urinary retention (AUR) further specified as being either precipitated or spontaneous, and to evaluate the potential benefit of finasteride therapy.
MATERIALS AND METHODS: Three thousand and forty men with moderate to severe symptoms of BPH and enlarged prostate ...
| Known for Urinary Retention | Aur Bph | 4 Years | Finasteride Therapy | Spontaneous Precipitated |
Transurethral resection versus incision of the prostate: a randomized, prospective study
[ PUBLICATION ]
OBJECTIVES: To evaluate longer term effects of transurethral resection (TURP) and incision (TUIP) of the prostate in randomized patients.
METHODS: In a randomized, prospective study, 120 patients with symptoms of bladder outlet obstruction caused by smaller benign prostates (estimated resectable weight less than 20 g) were assigned to TURP or TUIP. Patients were evaluated preoperatively and at intervals postoperatively as to urinary symptoms (Madsen's questionnaire), sexual function, and ...
| Known for Transurethral Resection | Turp Tuip | Incision Prostate | Followup Visits | Urinary Symptoms |
A new era in the surgical management of benign prostatic hyperplasia (BPH) has emerged in the past decade. A variety of less invasive treatment modalities have been introduced and well-established surgical treatments are being reassessed. Although progress has been made in the management of BPH, the substantial economic burden to the healthcare system caused by BPH emphasizes the importance of cost-effective treatment. Open prostatectomy is the most efficient BPH treatment for relieving ...
| Known for Benign Prostatic Hyperplasia | Prostate Turp | Surgical Management | Treatment Bph | Transurethral Resection |
OBJECTIVES: To evaluate sequelae and estimate quality of life utilizing a survey instrument in 133 consecutive patients who have undergone definitive radiation therapy for localized prostate cancer.
METHODS: All patients reported on have been followed for 14 to 60 months (median, 31 months) after radiation therapy and only patients with definitive prostate radiation therapy are included. Of the patients still alive at time of follow-up, 115 were mailed the questionnaire. Data regarding ...
| Known for Radiation Therapy | Prostate Cancer | Time Questionnaire | Incontinence Aged | Sequelae Patients |
PURPOSE: We determine outcomes after 5 years of followup for men who were randomized to receive transurethral resection or watchful waiting for moderate symptoms of benign prostatic hyperplasia.
MATERIALS AND METHODS: A total of 556 patients were evaluated up to 60 months after randomization providing 966 patient-years of followup for transurethral prostatic resection and 990 for watchful waiting. Patients randomized to watchful waiting were evaluated according to whether they remained ...
| Known for Watchful Waiting | Prostatic Hyperplasia | Veterans Affairs | Moderate Symptoms | Transurethral Resection |
THE EFFECTS OF TRANSURETHRAL NEEDLE ABLATION AND RESECTION OF THE PROSTATE ON PRESSURE FLOW URODYNAMIC PARAMETERS
[ PUBLICATION ]
PURPOSE: We evaluated the effects of transurethral needle ablation and prostate resection on pressure flow urodynamic parameters in men with benign prostatic hyperplasia (BPH), compared symptomatic and objective parameters of efficacy 6 months after initial treatment, and determined whether urodynamic assessment may predict symptomatic improvement.
MATERIALS AND METHODS: We enrolled 121 patients with clinical BPH, American Urological Association symptom index of 13 or greater and maximum ...
| Known for Transurethral Needle Ablation | Pressure Flow | 6 Months | Resection Prostate | Initial Treatment |
Key People For Benign Prostatic Hyperplasia
Reginald C Bruskewitz:Expert Impact
Concepts for whichReginald C Bruskewitzhas direct influence:Benign prostatic hyperplasia, Prostatic hyperplasia, Transurethral resection, Watchful waiting, Radical prostatectomy, Benign prostatic, Transurethral incision, Radiation therapy.
Reginald C Bruskewitz:KOL impact
Concepts related to the work of other authors for whichfor which Reginald C Bruskewitz has influence:Prostate cancer, Benign prostatic hyperplasia, Erectile dysfunction, Transurethral resection, Urinary tract, Quality life, Sexual function.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |